8/30/2023 0 Comments Dropshare 5Release notes were unavailable when this listing was updated.History of recent uploads including preview images in the drop down menu.Optionally automatically uploads screenshots taken with OS X and copies the sharing URL to your clipboard Looking for alternatives to Dropshare Find out how Dropshare stacks up against its competitors with real user reviews, pricing information, and what features they offer.Uploads every file and even directories (which will be compressed prior uploading).Login (SCP over SSH) via password (keyboard authentication) or private key (public key authentication).Dropshare works with Secure Copy (SCP over SSH), therefore either a password (for keyboard authentication) or a private key (for public key authentication) is required. To have Dropshare working correctly, you have to have a server of your choice and a working SSH user account at your disposal. No longer have your shared files on servers provided by companies you don’t even know – easily set up Dropshare and share whatever file you like by only drag&dropping it on the menubar icon, securely saved on your own server. Dropshare is a menu bar app that enables you to drag & drop upload files, screenshots and even directories to your own server to share them with anyone you like. Nuvama maintained its 'hold' added to await evidence of sustainable volume uptick and turnaround in Suburban before turning constructive on the stock.Dropshare is your very own secure file sharing tool. Hence, we increase our target multiple to 45 times, from 40 times," it added while revising the target price to Rs 2,370 from Rs 2,100 earlier. "We share management’s views that pricing pressure seen in the last year and a half is behind, and industry gears for price hikes. Its efforts in improving cost is visible given mere 3 per cent opex growth, said Nuvama Institutional Equities. Price hikes and better test mix coupled with lower opex led to impressive EBITDA margin of 27 per cent. Non-covid revenues grew 10 per cent YoY, of which, volume growth was a mere 2.5 per cent. We retain a 'sell' rating with a fair value of Rs 1,675," it added, signaling a 33 per cent crash in the price from its previous close.Īs on March 31, 2023, the pan-India diagnostic chain player had 277 clinical laboratories, 5,102 Patient Service Centers (PSCs) and 10,938 Pick-up Points (PUPs)ĭr Lal’s Q1FY24 revenue was in-line, but EBITDA and PAT beat estimates. At 53 time FY2025E EPS, valuations remain elevated. In our view, the increasing sanity in diagnostics pricing is well captured in the recovery built in our estimates for the company. "Furthermore, traction in Suburban stays lower than expectations. no credit card required Personal use only 1 GB Transfer. Monthly Billing Annual Billing (-15) Free. It sees sales to be line, while higher aggression by Metropolis in Delhi NCR is a monitorable Dropshare Cloud is a subscription-based storage service to be used with Dropshare for macOS & iOS. However, sluggishness in organic non-Covid patient volumes remains a concern, said Kotak Institutional Equities. Also, non-covid revenues and performance continue to be a challenge.ĭr Lal Pathlabs's 1QFY24 EBITDA beat estimates, driven by lower SG&A expenses, a better test mix and seasonality boost. However, the brokerage firms continue to remain negative on the stock as they believe that most of the positives are majorly priced in the prices and expensive valuations leave little headroom for the further upside. The stock had settled at Rs 2,483.50 on Thursday. Shares of Dr Lal Pathlabs dropped about 5 per cent to Rs 2,366.45 on Friday, before recovering slightly, as the company commanded a total market capitalization of close to Rs 20,000 crore. EBITDA for the quarter surged 24.4 per cent YoY to Rs 146 crore, with EBITDA margins improving 360 basis points YoY to 27 per cent. Revenues increased about 8 per cent to Rs 541 crore in Q1FY24, while the non-covid revenues advanced by 10 per cent YoY to Rs 528 crore in Q1FY24, Covid testing revenues stood at Rs 13 crore in the same period. Dr Lal PathLabs reported Rs 58 crore net profit during the corresponding period of previous year. However, the brokerage firms are not much enthused by the company's Q1 performance, with some analysts expecting the stock to lose one-third of its value.ĭr Lal PathLabs reported a 44 per cent year-on-year YoY rise in net profit at Rs 84 crore in the first quarter ended Jled by growth in non-covid testing and higher realizations. Shares of Dr Lal Path Labs dropped about 5 per cent during the early trading session on Friday despite the company reporting a strong performance in the June 2023 quarter.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |